Despite its ageing population and growing need for healthcare, South Korea had just 2.6 doctors per 1,000 inhabitants in 2022, one of the lowest numbers among developed nations. To deal with the shortage, the government has created a plan to boost the yearly number of medical students, but this has caused widespread doctor walkouts and…
Writing in DIA’s Global Forum magazine for April 2024 on behalf of DIA Japan’s Open Innovation Community Fumitaka Noji, Takeshi Kono, and Makoto Nagaoka look at how the gap between Japan’s academia and pharma companies can best be bridged to fully reap the benefits of innovation. Although open innovation in drug research and development has long…
Australia’s international outlook, strong science base, multi-ethnic English-speaking population and high educational and regulatory standards make it an attractive location to undertake clinical trials for medicines and vaccines. These fundamentals were foregrounded during the COVID-19 pandemic, when Australia was able to pivot quickly and develop capabilities in technology and tele-monitoring in clinical trials, opening further…
Toshi Tominaga of Keio University Hospital, writing in the January 2023 edition of the DIA Global Forum magazine, outlines some recent updates to Japanese drug registration legislation, including how domestically generated academic clinical data can be utilised. Japan’s current regulatory framework for investigator-initiated trials (IITs) of drug candidates seems fragmented. IITs are categorized as…